Issue 19 - The Cancer Letter

<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

Vol.

33

No.

19

May 18, 2007May 18, 2007

Free

DOWNLOAD THE PDF

After ODAC: Questions On ESA Claims, Advertising, Reimbursement Gain Urgency.

Amgen Claimed QOL Benefit Despite FDA Label Change.

“Miracle-Gro for Cancer?” ODAC Members Vent At Amgen And J&J Over Claims, Advertising.

FDA Begins To Examine Its Role In Allowing Misleading Consumer Advertising.

CMS Proposal To Limit ESA Use Is Too Much, Too Fast, Critics Say.

Recent Issues

Volume 52 | Issue 33 - September 11, 2026

Volume 52 | Issue 32 - August 14, 2026

Volume 52 | Issue 31 - August 07, 2026

Volume 52 | Issue 30 - July 31, 2026

Volume 52 | Issue 29 - July 24, 2026

Volume 52 | Issue 28 - July 17, 2026